Bifogade filer
2curex Årsredovisning Och Koncern 2023
Kurs
-12,50%
Likviditet
0,04 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-27 | 15:00 | Bokslutskommuniké 2024 |
| 2024-12-18 | N/A | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-11-14 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-26 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2023-02-10 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-02 | - | Extra Bolagsstämma 2019 |
| 2019-03-01 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2018-05-28 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.
The Annual Report for 2023 for 2cureX AB (publ), 559128-0077, is now available.
The annual report, along with the auditor's report for 2cureX AB and the 2cureX group, as well as complete proposals for resolutions and proxy forms, can be accessed at the company's office at 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark, and on the company's website (www.2curex.com).
Malmö in May 2024
2cureX AB (publ)
The Board of Directors
For more information about 2cureX:
Ole Thastrup, CEO
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB